| Primary |
| Product Used For Unknown Indication |
24.8% |
| Drug Exposure During Pregnancy |
17.0% |
| Hypertension |
9.2% |
| Gastritis |
7.8% |
| Duodenal Ulcer |
6.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
6.4% |
| Drug Use For Unknown Indication |
3.5% |
| Abscess Intestinal |
2.8% |
| Oesophageal Carcinoma |
2.8% |
| Ulcer |
2.8% |
| Anxiety |
2.1% |
| Gastric Ulcer |
2.1% |
| Gastrointestinal Disorder |
2.1% |
| Oesophagitis |
2.1% |
| Pain |
2.1% |
| Gastrooesophageal Reflux Disease |
1.4% |
| Inflammation |
1.4% |
| Peptic Ulcer |
1.4% |
| Abdominal Disorder |
0.7% |
| Abdominal Pain |
0.7% |
|
| Pneumonia |
14.5% |
| Intra-uterine Death |
9.1% |
| Hepatic Function Abnormal |
7.3% |
| Incorrect Route Of Drug Administration |
7.3% |
| Pruritus |
7.3% |
| Bezoar |
5.5% |
| Medication Error |
5.5% |
| Reye's Syndrome |
5.5% |
| Drug Ineffective |
3.6% |
| Lymphocyte Stimulation Test Positive |
3.6% |
| Malaise |
3.6% |
| Maternal Drugs Affecting Foetus |
3.6% |
| Neonatal Asphyxia |
3.6% |
| Pulmonary Embolism |
3.6% |
| Rash |
3.6% |
| Tremor |
3.6% |
| Vomiting |
3.6% |
| Abdominal Distension |
1.8% |
| Agranulocytosis |
1.8% |
| Anaphylactic Reaction |
1.8% |
|
| Secondary |
| Product Used For Unknown Indication |
48.7% |
| Drug Use For Unknown Indication |
16.3% |
| Rheumatoid Arthritis |
4.4% |
| Gastrointestinal Disorder |
4.3% |
| Hypertension |
3.7% |
| Drug Therapy |
2.7% |
| Erythema Multiforme |
2.3% |
| Pain |
2.3% |
| Nutritional Support |
1.9% |
| Prophylaxis |
1.9% |
| Sleep Disorder |
1.9% |
| Diarrhoea |
1.5% |
| Hyperthermia |
1.5% |
| Gastric Disorder |
1.1% |
| Cardiac Failure |
1.0% |
| Intraoperative Care |
1.0% |
| Antibiotic Prophylaxis |
0.9% |
| Infection |
0.9% |
| Muscle Spasms |
0.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.9% |
|
| Vestibular Disorder |
12.9% |
| Visual Impairment |
8.1% |
| Cellulitis |
6.5% |
| Leukocytoclastic Vasculitis |
6.5% |
| Weight Decreased |
6.5% |
| Acute Generalised Exanthematous Pustulosis |
4.8% |
| Constipation |
4.8% |
| Diarrhoea |
4.8% |
| Insomnia |
4.8% |
| Medication Error |
4.8% |
| Renal Disorder |
4.8% |
| Tremor |
4.8% |
| Aphasia |
3.2% |
| Death |
3.2% |
| Dehydration |
3.2% |
| Erythema Multiforme |
3.2% |
| False Positive Laboratory Result |
3.2% |
| Lymphocyte Stimulation Test Positive |
3.2% |
| Pain |
3.2% |
| Pneumocystis Jiroveci Pneumonia |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.3% |
| Drug Use For Unknown Indication |
22.8% |
| Prophylaxis |
6.8% |
| Hypertension |
5.9% |
| Pain |
4.2% |
| Rheumatoid Arthritis |
4.1% |
| Gastrooesophageal Reflux Disease |
3.5% |
| Depression |
2.5% |
| Nausea |
2.2% |
| Osteoporosis |
2.2% |
| Gastritis |
1.9% |
| Non-small Cell Lung Cancer |
1.8% |
| Insomnia |
1.8% |
| Gastric Ulcer |
1.8% |
| Multiple Myeloma |
1.7% |
| Constipation |
1.6% |
| Gastric Cancer |
1.6% |
| Diabetes Mellitus |
1.5% |
| Premedication |
1.5% |
| Crohn's Disease |
1.5% |
|
| Vomiting |
18.4% |
| White Blood Cell Count Decreased |
8.5% |
| Pain |
7.8% |
| Weight Decreased |
7.2% |
| Death |
6.6% |
| Pneumonia |
5.1% |
| Weight Increased |
4.9% |
| Urinary Tract Infection |
4.8% |
| Pyrexia |
4.3% |
| Thrombocytopenia |
4.2% |
| Nausea |
3.6% |
| Sepsis |
3.4% |
| Diarrhoea |
3.3% |
| Myocardial Infarction |
2.8% |
| Drug Ineffective |
2.7% |
| Rash |
2.5% |
| Wheezing |
2.5% |
| Dyspnoea |
2.4% |
| Septic Shock |
2.4% |
| Upper Gastrointestinal Haemorrhage |
2.4% |
|
| Interacting |
| Zygomycosis |
29.4% |
| Convulsion Prophylaxis |
13.7% |
| Prophylaxis |
11.8% |
| Gastrooesophageal Reflux Disease |
7.8% |
| Hypertension |
7.8% |
| Convulsion |
5.9% |
| Chest Pain |
3.9% |
| Erectile Dysfunction |
3.9% |
| Oesophagitis |
3.9% |
| Wound Treatment |
3.9% |
| Hypercholesterolaemia |
2.0% |
| Hypothyroidism |
2.0% |
| Rhizopus Infection |
2.0% |
| Sinusitis |
2.0% |
|
| Vomiting |
31.6% |
| Drug Interaction |
15.8% |
| Hearing Impaired |
10.5% |
| Malabsorption |
10.5% |
| Drug Level Decreased |
5.3% |
| Mood Altered |
5.3% |
| Multi-organ Failure |
5.3% |
| Prescribed Overdose |
5.3% |
| Pulmonary Eosinophilia |
5.3% |
| Pulmonary Haemosiderosis |
5.3% |
|
